Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W9NH
|
|||
| Former ID |
DCL001122
|
|||
| Drug Name |
Tacedinaline
|
|||
| Synonyms |
Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 2 | [1], [2] | |
| Company |
National Cancer Institute (NCI)
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H15N3O2
|
|||
| Canonical SMILES |
CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N
|
|||
| InChI |
1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)
|
|||
| InChIKey |
VAZAPHZUAVEOMC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 112522-64-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6897908, 8151773, 12014151, 14848338, 29221901, 46519444, 47207646, 49875144, 57321429, 76461531, 87226490, 93619303, 103137194, 103537395, 104301487, 117537664, 118843066, 121363787, 123391000, 124360040, 125338021, 126671706, 129449051, 134345068, 134964212, 135074618, 135698188, 136367989, 137022499, 137237670, 141654160, 144115829, 152029810, 152159635, 152186807, 160871335, 162012039, 162205195, 162248589, 163121968, 163621122, 163686462, 164193980, 164224003, 164824268, 172095414, 172911911, 175608160, 179148456, 184538256
|
|||
| ChEBI ID |
CHEBI:90195
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8367). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002525) | |||
| REF 3 | Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. | |||
| REF 4 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.